Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Study to Provide Berotralstat Access to Subjects With Type 1 and 2 Hereditary Angioedema Who Were Previously Enrolled in Berotralstat Studies

NCT04933721 is registered in ClinicalTrials.gov with BioCryst Pharmaceuticals as lead sponsor.

NCT NCT04933721
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04933721 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Study to Provide Berotralstat Access to Subjects With Type 1 and 2 Hereditary Angioedema Who Were Previously Enrolled in Berotralstat Studies
Lead sponsor
BioCryst Pharmaceuticals
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
July 23, 2021
Completion date
August 31, 2031
Enrollment
139 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

hae, hereditary angioedema